Clin Cancer Res: Nivolumab significantly prolongs long-term survival in advanced esophageal squamous cell carcinoma

Currently, there are limited long-term prognostic data on patients with advanced esophageal squamous cell carcinoma (ESCC) treated with immune checkpoint inhibitors
.

This article reports the three-year follow-up of nivolumab or chemotherapy (paclitaxel or docetaxel) in previously treated patients with esophageal squamous cell carcinoma from the ATTRACTION-3 trial

immunity

The ATTRACTION-3 trial is a multicenter, open-label, randomized, controlled Phase 3 clinical trial recruiting patients 18 years of age and older with unresectable advanced or recurrent esophageal squamous cell carcinoma, randomized (1:1) to Two groups received nivolumab or chemotherapy (paclitaxel or docetaxel)
.

The primary endpoints were overall survival (OS) and all-cause mortality

Overall survival in both groups

Overall survival in both groups

A total of 419 patients were enrolled: 210 in the nivolumab group and 209 in the chemotherapy group
.

As of May 25, 2020, with a minimum follow-up of 36.

Overall survival was significantly longer in the nivolumab group compared to the chemotherapy group The median overall survival in the nivolumab group was longer than that in the chemotherapy group , regardless of whether the response was achieved or not

Progression-free survival in both groups

Progression-free survival in both groups

Grade 3 or higher treatment-related adverse events were reported in 40 (19.
1%) and 133 (63.
9%) patients in the nivolumab and chemotherapy groups, respectively
.

The most common adverse reactions were skin and gastrointestinal reactions

In conclusion, in previously treated patients with unresectable advanced esophageal squamous cell carcinoma, the use of nivolumab as second-line therapy significantly improved long-term survival outcomes compared with chemotherapy
.

Compared with the chemotherapy group, nivolumab extended the survival time of patients with or without remission

For patients with previously treated unresectable advanced esophageal squamous cell carcinoma, the use of nivolumab as second-line therapy significantly improved long-term survival outcomes compared with chemotherapy for previously treated unresectable advanced esophageal squamous cell carcinoma Cancer patients, the use of nivolumab as second-line therapy can significantly improve long-term survival outcomes compared with chemotherapy

Original source:

Original source:

Morihito Okada, et al.

Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3 )